SEK 228.00
+1.80 (+0.80%)
SEK · as of 2026-08-20 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BONEX.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 3 observational
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage ProcedureNCT06555848observationalComposite Endpoint | — | Recruiting | Device: CERAMENT G | Osteomyelitis | 128 | Oct 2031 | ≤ 1,896 d | 2026-05-04 |
| CERAMENT G Device RegistryNCT06010433observationalPrimary Outcomes | — | Recruiting | Device: CERAMENT G | Chronic Osteomyelitis, Fracture Related Infection, Diabetic Foot Osteomyelitis | 100 | 2028-09-22 | in 762 d | 2025-09-26 |
| CERAMENT™| Bone Void Filler Device RegistryNCT04244942observationalUnexpected device performance will be collected as they occur at time of surgery and on an ongoing basis thereafter, with formal scheduled review at 12 and 18 months | — | Recruiting | Device: CERAMENT BVF | Orthopedic Disorder | 300 | 2028-03-30 | in 586 d | 2025-09-29 |
| Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial FracturesNCT02820363Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.Randomized · Single-masked · Treatment | Not applicable | Completed | Device: CERAMENT|G · Procedure: SOC treatment | Tibial Fracture | 201 | 2021-07-31actual | — | 2021-08-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-21